Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 6Terminated 4Active not recruiting 3Recruiting 2Withdrawn 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Hairy Cell 1Hematopoietic and Lymphoid System Neoplasm 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × CT-P10 × Clear all
NCT06965114 2026-05-13

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
25 enrolled

Hematopoietic and Lymphoid System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡